Premium
Synthesis of 14 C‐labelled (R)‐α‐amino‐6,7‐dimethyl‐3‐(phosphonomethyl)‐2‐quinolinepropanoic acid
Author(s) -
Swahn BrittMarie,
Andersson Fredrik,
Pelcman Benjamin,
Söderberg Johan,
Claesson Alf
Publication year - 1997
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(199703)39:3<259::aid-jlcr968>3.0.co;2-e
Subject(s) - chemistry , methyl iodide , reagent , quinoline , phosphonate , nmda receptor , derivative (finance) , iodide , zinc , medicinal chemistry , stereochemistry , organic chemistry , biochemistry , receptor , financial economics , economics
The NMDA antagonist (R)‐α‐amino‐6,7‐dimethyl‐3‐(phosphonomethyl)‐quinolinepropanoic acid 1 was [ 14 C]‐labelled at the 6‐methyl group. The quinoline synthesis started from 4‐bromo‐3‐methylaniline and the radiolabel was introduced late in the synthetic scheme. The synthesis was accomplished by a NiCl 2 (dppp) 2 ‐catalyzed coupling of the 6‐bromoquinoline derivative 6 with a zinc reagent made from [ 14 C]‐methyl iodide. © 1997 John Wiley & Sons, Ltd.